FDA approves Pfizer's rheumatoid arthritis treatment

Share this article:
FDA approves Pfizer's rheumatoid arthritis treatment
FDA approves Pfizer's rheumatoid arthritis treatment
Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate. Xeljanz can be used with methotrexate and certain other treatments. Industry analysts have predicted the new drug, also known as tofacitinib, could grow to sales of $3 billion annually. Xeljanz is taken in 5-milligram pills twice daily.  About 1.3 million people in the United States suffer from rheumatoid arthritis, which can cause problems in wound healing.
Share this article:

More in Products

LINK Innovation Competition crowns Walalight best

The Walalight™ system, which simulates natural sunlight exposure and promotes regular circadian rhythms, won first place at the 2014 LINK Innovation Competition on Monday in Chicago.

Nestlé Professional MINOR adds low-sodium, gluten-free base

Nestlé Professional MINOR adds low-sodium, gluten-free base

MINOR's Low Sodium Gluten Free Base is available in chicken, beef and vegetable, Nestle Professional announced.

Larson Electronics debuts mobile power distribution system

Larson Electronics debuts mobile power distribution system

The Larson Electronics MDC-240-100MB-8X120 temporary power distribution system is now available for those who need to use power sources independently of a work area.